Scaling omics approaches to population size
See talks from the Scaling omics approaches to population size biobank symposium, 11th-12th November 2020
Human biological material combined with clinical and demographic registries are the most critical resources for translating the researchbased advances in molecular biology and advanced technologies into improved human health.
Human diversity as dictated by variation in the sequences of genomes can now be characterized in depth at the population scale. Coupled with longitudinal information about disease risk factors, causal processes and outcomes, an unparalleled opportunity currently exists to optimize prevention, diagnosis and treatment of many acute and chronic diseases.
Based on these prerequisites and world-class research communities, several Nordic biobanks have taken giant steps from merely being biorepositories to becoming excellent research communities for genetic epidemiology and translational medicine.
With this biobank symposium, we will bring together world-leading biobanks, researchers and experts in ethical, legal and societal implications to discuss how we can leverage the full potential of omics and achieve population-scale sample sizes. The technical side is important but so is the donor and political perspective.
The symposium is kindly sponsored by the Novo Nordisk Foundation.
Talks will also be made available as audio podcasts at PodBean.
Proteomics on a population-based scale
Matthias Mann
Max Planck Institute of Biochemistry and Novo Nordisk Foundation
Center for Protein Research
Genetics of metabolism in a population isolate - lessons from Greenland
Torben Hansen, Novo Nordisk Foundation Center for Basic Metabolic Research
The 500,000 sequencing initiative in the UK Biobank
Naomi Allen, Oxford University and UK Biobank
The FinnGen approach to understanding human disease
Mark Daly, Institute for Molecular Medicine Finland and Harvard Medical School
Genome-wide association study across pediatric central nervous system tumors implicates shared predisposition and points to 1q25.2 (PAPPA2) and 11p12 (LRRC4C) as novel candidate susceptibility loci.
Jon Foss-Skiftesvik, Rigshospitalet and Statens Serum Institut
Scaling Neonatal Metabolomics to Population Size.
Madeleine Ernst, Statens Serum Institut
Single-cell analysis of liver biopsies from obese patients – a new approach to understanding fatty liver disease.
Rikard G. Fred, Novo Nordisk Foundation Center for Basic Metabolic Research
Leveraging the potential of the Danish National Biobank
Lasse Boding, Danish National Biobank, Statens Serum Institut
Biobanking and precision medicine
Kristian Hveem, Norwegian University of Science and Technology
The Danish Biobanks and registers as perfect tools for research and precision medicine
Henrik Ullum, Copenhagen University Hospital
The Spanish perspective on cancer research
Eva Ortega Paino, Spanish National Cancer Research Centre (CNIO)
The Danish contribution to psychiatry through massive unbiased sample collections
Michael Christiansen, Statens Serum Institute and University of Copenhagen
Molecular prediction of inflammatory bowel disease
Tine Jess, Statens Serum Institut
Gut microbiome and its metabolic functions reflect healthy and unhealthy distribution profiles of lipoproteins.
Josue Castro, University of Copenhagen
Clinical potential of adoptive cell therapy with tumor infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients
Anders H. Kverneland, National Center for Cancer Immune Therapy
Program for Translational Hematology – Creating a platform for blood cancer research.
Katja Kaastrup, Rigshospitalet and University of Copenhagen
Does biobanking have room for ELSI debate anymore?
Aaro Tupasela, University of Helsinki
History of Biobanks
Peter Nilsson, Lund University
The future for donor consent
Klaus Høyer, University of Copenhagen
The political landscape, experiences from the first researcher in the Danish parliament
Stinus Lindgreen, Scientist and Politician. Member of Folketinget
Contact
Danish National Biobank
T. +45 5122 6605
@. mail@nationalbiobank.dk
View profile